APDN
Applied DNA Sciences, Inc.5.62
+1.35+31.6%
Oct 6, 4:00:01 PM EDT
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
7.26MP/E (TTM)
-Basic EPS (TTM)
-57.12Dividend Yield
0%Recent Filings
10-Q
Q1 FY2026 results
BNB Plus posted Q1 FY2026 revenue of $565K, down 35% y/y from $870K yet product sales up 12% y/y to $555K on Therapeutic DNA strength while services cratered 97%. Gross margin slipped to 56% from 70%, but operating loss ballooned to $18.7M from $3.0M, driven by $9.4M consulting (warrants issued) and $5.2M digital asset losses in its new treasury pivot. Cash jumped to $2.5M on $24.9M net PIPE proceeds (cash/USDC/OBNB units); operating cash burn hit $5.5M. Equity swelled to $18.5M post-financings. Diluted EPS $-2.08 reconciles to 8.9M shares. Digital asset prices swing wildly.
8-K
Appoints blockchain expert Haft
BNB Plus Corp. appointed James Haft as independent director and Nominating Committee member on February 2, 2026, filling a board vacancy. Haft receives a $40,000 cash fee and options for 93,000 shares at $1.31, vesting quarterly over 12 months. His blockchain expertise bolsters BNB treasury and DeFi strategy. Board fills gap swiftly.
10-K
FY2025 results
BNB Plus pivoted to a digital asset treasury strategy post-fiscal year-end, raising $26.8M in October 2025 via private placement to accumulate BNB for yield generation, eclipsing legacy biotech ops. FY2025 revenues hit $2.1M, up from prior year on Therapeutic DNA product sales (+33% y/y), yet service revenues fell 31% amid restructuring; gross margins slipped to 39% from 46% on product mix shift. R&D spiked 67% to $6.0M, driven by $2.7M IPR&D impairment, fueling $16.0M operating loss. Q4 wrapped restructurings slashing headcount 72% cumulatively for ~70% payroll cuts. Post-year, LineaRx eyes FY26Q1 loss narrowing. BNB price volatility threatens treasury value.
8-K
Stockholders approve warrants, shares
BNB Plus Corp. stockholders approved three key proposals at the December 12, 2025 special meeting. They greenlit exercisability of pre-funded warrants and common stock warrants from a September 29 securities purchase agreement, boosted authorized common shares from 200M to 500M, and added 5M shares to the 2020 Equity Incentive Plan. Warrants now unlock capital access. Strong support minimizes dilution risk.
A
Agilent Technologies, Inc.
139.19-1.41
CDNA
CareDx, Inc.
19.36-0.55
DGX
Quest Diagnostics Incorporated
178.66-5.45
DHR
Danaher Corporation
224.70-3.83
IDXG
Interpace Biosciences, Inc.
1.14-0.02
ILMN
Illumina, Inc.
131.56-3.36
NNNN
Anbio Biotechnology
28.01-0.39
QGEN
Qiagen N.V.
45.01-0.43
TWST
Twist Bioscience Corporation
31.13+0.06
WGS
GeneDx Holdings Corp.
141.72-8.89